<?xml version='1.0' encoding='utf-8'?>
<document id="28535410"><sentence text="Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters." /><sentence text="Perampanel, a selective, noncompetitive AMPA receptor antagonist, is indicated as adjunctive therapy for the treatment of partial seizures with or without secondarily generalized seizures and primary generalized tonic-clonic seizures in patients with epilepsy aged 12years and older" /><sentence text=" In vitro studies and Phase I trials indicate that perampanel is metabolized almost exclusively by CYP3A, with an elimination half-life (t1/2) averaging approximately 105h" /><sentence text=" Understanding of pharmacokinetic (PK) interactions-enzyme inhibition or induction-and anticipating their occurrence are important for management of patients with epilepsy" /><sentence text=" Here we report PK results from a Phase I drug-drug interaction (DDI) study (Study 005) combining perampanel with the CYP3A inhibitor ketoconazole, as well as supplementary in silico predictions further exploring this interaction"><entity charOffset="134-146" id="DDI-PubMed.28535410.s5.e0" text="ketoconazole" /></sentence><sentence text="" /><sentence text="A Phase I, randomized, open-label, two-period, two-treatment, two-way crossover study was conducted in 26 healthy adult male volunteers" /><sentence text=" Subjects were randomized to 1 of 2 treatment sequences" /><sentence text=" In one period, subjects received a single 1-mg fasting dose of perampanel (Day1); in the other period, subjects received ketoconazole 400mg once daily for 10days with a single 1-mg perampanel dose while fasting (Day3)"><entity charOffset="122-134" id="DDI-PubMed.28535410.s9.e0" text="ketoconazole" /></sentence><sentence text=" Blood samples were drawn at multiple time points up to 288h after the perampanel dose" /><sentence text=" Pharmacokinetic parameters of perampanel were calculated by noncompartmental analysis, and safety was recorded" /><sentence text=" An integrated, physiologically based PK model built in SimcypÂ® provided additional insight into this interaction" /><sentence text=" Drug-drug interaction intensity was measured by the ratio of systemic exposure (area under plasma concentration-time curve [AUC]) of perampanel in the presence or absence of concomitant ketoconazole"><entity charOffset="187-199" id="DDI-PubMed.28535410.s13.e0" text="ketoconazole" /></sentence><sentence text="" /><sentence text="Single oral doses of 1mg perampanel and once-daily oral doses of ketoconazole 400mg were safe and well tolerated"><entity charOffset="25-35" id="DDI-PubMed.28535410.s15.e0" text="perampanel" /><entity charOffset="65-77" id="DDI-PubMed.28535410.s15.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.28535410.s15.e0" e2="DDI-PubMed.28535410.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28535410.s15.e0" e2="DDI-PubMed.28535410.s15.e1" /></sentence><sentence text=" Maximum perampanel plasma concentration (Cmax) and time to Cmax showed no apparent differences when perampanel was administered alone versus with ketoconazole"><entity charOffset="147-159" id="DDI-PubMed.28535410.s16.e0" text="ketoconazole" /></sentence><sentence text=" Ketoconazole co-administration resulted in an approximate 20% increase in perampanel AUC (P&lt;0"><entity charOffset="1-13" id="DDI-PubMed.28535410.s17.e0" text="Ketoconazole" /></sentence><sentence text="001)" /><sentence text=" This increase, although statistically significant, was a&lt;2" /><sentence text="0-fold AUC change and alone would suggest a modest effect of ketoconazole"><entity charOffset="61-73" id="DDI-PubMed.28535410.s20.e0" text="ketoconazole" /></sentence><sentence text=" To further explore these results, DDI simulations were performed to query the findings and test additional study conditions" /><sentence text=" Using the actual trial conditions of Study 005, the simulations also predicted an AUC ratio increase &lt;2-fold, providing verification of the simulation assumptions and the modest effect of ketoconazole for 10days"><entity charOffset="189-201" id="DDI-PubMed.28535410.s22.e0" text="ketoconazole" /></sentence><sentence text=" Simulations further suggested that an interaction effect of ketoconazole on perampanel exposure (&gt;2-fold) of potential clinical significance could be predicted when using larger doses of ketoconazole (e"><entity charOffset="61-73" id="DDI-PubMed.28535410.s23.e0" text="ketoconazole" /><entity charOffset="77-87" id="DDI-PubMed.28535410.s23.e1" text="perampanel" /><entity charOffset="188-200" id="DDI-PubMed.28535410.s23.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.28535410.s23.e0" e2="DDI-PubMed.28535410.s23.e0" /><pair ddi="false" e1="DDI-PubMed.28535410.s23.e0" e2="DDI-PubMed.28535410.s23.e1" /><pair ddi="false" e1="DDI-PubMed.28535410.s23.e0" e2="DDI-PubMed.28535410.s23.e2" /><pair ddi="false" e1="DDI-PubMed.28535410.s23.e1" e2="DDI-PubMed.28535410.s23.e1" /><pair ddi="false" e1="DDI-PubMed.28535410.s23.e1" e2="DDI-PubMed.28535410.s23.e2" /></sentence><sentence text="g" /><sentence text=", 200mg every 6h) coadministered for a greater time period (e" /><sentence text="g" /><sentence text=", 30days), with AUC ratio as high as 3" /><sentence text="36" /><sentence text=" Additionally, simulations suggested that a significant interaction with co-administration of perampanel and an inhibitor more potent than ketoconazole (such as itraconazole) could not be ruled out"><entity charOffset="139-151" id="DDI-PubMed.28535410.s29.e0" text="ketoconazole" /><entity charOffset="161-173" id="DDI-PubMed.28535410.s29.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.28535410.s29.e0" e2="DDI-PubMed.28535410.s29.e0" /><pair ddi="false" e1="DDI-PubMed.28535410.s29.e0" e2="DDI-PubMed.28535410.s29.e1" /></sentence><sentence text="" /><sentence text="Selecting an appropriate study design is critical to fully characterize the PK interaction for drugs such as perampanel that have a long t1/2" /><sentence text=" Although a negligible effect on perampanel PK was observed following co-administration of ketoconazole 400mg/day for 10days, this is likely due in part to the relatively brief co-administration period of ketoconazole and perampanel (&lt;3 times the t1/2 of perampanel)"><entity charOffset="91-103" id="DDI-PubMed.28535410.s32.e0" text="ketoconazole" /><entity charOffset="205-217" id="DDI-PubMed.28535410.s32.e1" text="ketoconazole" /><entity charOffset="222-232" id="DDI-PubMed.28535410.s32.e2" text="perampanel" /><entity charOffset="255-265" id="DDI-PubMed.28535410.s32.e3" text="perampanel" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e0" e2="DDI-PubMed.28535410.s32.e0" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e0" e2="DDI-PubMed.28535410.s32.e1" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e0" e2="DDI-PubMed.28535410.s32.e2" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e0" e2="DDI-PubMed.28535410.s32.e3" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e1" e2="DDI-PubMed.28535410.s32.e1" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e1" e2="DDI-PubMed.28535410.s32.e2" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e1" e2="DDI-PubMed.28535410.s32.e3" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e2" e2="DDI-PubMed.28535410.s32.e2" /><pair ddi="false" e1="DDI-PubMed.28535410.s32.e2" e2="DDI-PubMed.28535410.s32.e3" /></sentence><sentence text=" While short-term administration of a CYP3A inhibitor may not significantly increase perampanel exposure, such increases may be expected following chronic and larger dosing or with a more potent inhibitor" /><sentence text="" /></document>